Drug Trial Radar · NCT07140393
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 28, 2025
Primary completion
Oct 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.
Conditions
- Solid Tumor
Interventions
HRS-4508+ CapecitabineDrug
HRS-4508+ Capecitabine
HRS-4508+ TrastuzumabDrug
HRS-4508+ Trastuzumab
HRS-4508+ Trastuzumab+ PertuzumabDrug
HRS-4508+ Trastuzumab+ Pertuzumab
HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxelDrug
HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel
HRS-4508+ Trastuzumab + Nab-paclitaxelDrug
HRS-4508+ Trastuzumab + Nab-paclitaxel
HRS-4508+ Trastuzumab+ CapecitabineDrug
HRS-4508+ Trastuzumab+ Capecitabine
Trastuzumab+ CapecitabineDrug
Trastuzumab+ Capecitabine
Trastuzumab+ PertuzumabDrug
Trastuzumab+ Pertuzumab
HRS-4508+SHR-A1811Drug
HRS-4508+SHR-A1811
HRS-4508+ Trastuzumab+ Pertuzumab+ Docetaxel+ CarboplatinDrug
HRS-4508+ Trastuzumab+ Pertuzumab+ Docetaxel+ Carboplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- HRS4508 DLTTime frame: 3 weeks
- HRS4508 MTDTime frame: 12 weeks
- HRS4508 RP2DTime frame: 12 weeks
- The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)Time frame: 2 years
- Objective response rate (ORR)Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.